Irvine Scientific Expands R&D Capabilities in Southern California
Irvine Scientific (Santa Ana, CA) today announced the expansion of its Orange County, CA, offices and laboratories, with the addition of a 40,000 square foot purpose-built R&D center at Irvine, CA. It is reported that new building will contain other departments that currently reside within its southern California-based headquarters, enabling the company to expand other capabilities, such as media customization for customers. Along with the facilities in Santa Ana, the new facility increases the total space occupied by Irvine Scientific in Orange County to over 140,000 square feet. For more information visit www.irvinesci.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
